George Nassief

Mr. George Nassief

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
JPJordan Phillipps
Jordan Phillipps
GNGeorge Nassief
George Nassief
RMRenee Morecroft
Renee Morecroft
TATolulope Adeyelu
Tolulope Adeyelu
AEAndrew Elliott
Andrew Elliott
George AnsstasGeorge Ansstas
George Ansstas
Modern advancements in targeted therapy and immunotherapy have significantly improved survival outcomes for advanced melanoma; however, there remains a need for novel approaches to overcome disease progression and treatment resistance. In recent years, PARPi therapy has shown great promise both as a single regimen and in combination with other therapeutics in melanoma. Here, we describe three unique cases of advanced BRAF V600 mutated melanoma that progressed on targeted BRAF/MEK agents that subsequently exhibited partial to near-complete responses to combinatory PARPi and BRAF/MEK inhibitors. This highlights both a potential synergy underlying this combinatory approach and its efficacy as a treatment option for patients with advanced melanoma refractory to targeted and/or immunotherapies. Prospective clinical trials are needed to explore this synergic effect in larger melanoma cohorts to investigate this combination for treating refractory advanced melanoma.

Verified
Journal Article
Open access
PDF file
GNGeorge Nassief
George Nassief
AAAngela Anaeme
Angela Anaeme
KMKaren Moussa
Karen Moussa
AMAbdallah N. Mansour
Abdallah N. Mansour
George AnsstasGeorge Ansstas
George Ansstas
Malignant melanoma outcomes have drastically changed in recent years due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients still experience intolerable side effects, therapy resistance, and disease progression on ICI therapy. Therefore, there remains a need for novel therapeutics that address this gap in treatment options. Cell-based therapies have gained wide attention as a therapeutic option that could address this gap in treatment options for advanced melanoma. These therapies work by extracting certain cell types produced in the human body such as T-cells, modifying them based on a specific target, and transfusing them back into the patient. In the realm of cancer therapy, cell-based therapies utilize immune cells to target tumor cells while sparing healthy cells. Recently, the Food and Drug Administration (FDA) has approved the usage of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced melanoma. This came following recent results from the C-144-01 study (NCT02360579), which demonstrated the efficacy and safety of TILs in metastatic melanoma patients who otherwise failed on standard ICI/targeted therapy. Thus, the results of this trial as well as the recent FDA approval have proven the viability of utilizing cell-based therapies to fill the gap in treatment options for patients with advanced melanoma. This review aims to provide a comprehensive overview of major cell-based therapies that have been utilized in melanoma by delineating results of the most recent multi-center phase II/ III clinical trials that evaluate the efficacy and safety of major cell-based therapies in melanoma. Additionally, we provide a summary of current limitations in each cell-based therapeutic option as well as a future direction of how to further extrapolate these cell-based therapies in advanced melanoma.

9 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GNGeorge Nassief
George Nassief
AAAngela Anaeme
Angela Anaeme
KMKaren Moussa
Karen Moussa
DCDavid Chen
David Chen
George AnsstasGeorge Ansstas
George Ansstas
Skin cancer prognosis has greatly improved recently due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients with advanced skin cancer still experience immunotherapy resistance and disease progression during ICI treatment, thus calling for novel therapeutics which address this treatment gap. Talimogene laherparepvec (T-VEC) has gained popularity in recent years as a viable treatment option for patients with skin cancer. In preclinical studies, T-VEC demonstrated both a direct anti-tumor effect in injected lesions as well as a systemic immune-mediated effect in non-injected lesions, which could pose additional benefits when combined with ICI therapy. Following promising results from the OPTiM trial, the Food and Drug Administration (FDA) approved the usage of T-VEC as a single agent in advanced melanoma. However, the MASTERKEY-265 trial demonstrated that adding T-VEC to pembrolizumab did not offer additional clinical benefit in patients with melanoma. Nevertheless, the promising efficacy of T-VEC and its approval by the FDA helped oncolytic viruses (OVs) gain wide attention in cancer therapy, and extensive research has been undertaken to evaluate the usage of OVs in other tumors such as sarcomas and breast cancers. Here, we provide a review of clinical results from 2022 to 2024 that investigate the efficacy and safety of OVs as a monotherapy or in combination with other therapies in skin malignancies. Furthermore, we delineate the current limitations in OV utilization and outline future directions to enhance clinical outcomes for patients with skin malignancies receiving OV-based therapies.

1 January 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
GNGeorge Nassief
George Nassief
TATolulope Adeyelu
Tolulope Adeyelu
AEAndrew Elliott
Andrew Elliott
JPJordan Phillipps
Jordan Phillipps
RMRenee Morecroft
Renee Morecroft
George AnsstasGeorge Ansstas
George Ansstas
PURPOSE: Homologous recombination deficiency (HRD) results in DNA instability in tumor cells and contributes to tumor pathogenesis. Although HRD-directed therapies are established in other cancers, their role in skin cancers remains unclear. Given the poor response to standard therapies in skin cancer subtypes like acral and mucosal melanoma, we aimed to characterize the prevalence of HRD across skin cancer subtypes, evaluate its correlation with immune checkpoint inhibitor (ICI) response biomarkers, and assess its prognostic relevance in patients treated with immunotherapy (IO). METHODS: A total of 2,508 patients with skin cancer underwent molecular profiling including whole-exome sequencing, whole-transcriptome sequencing, and immunohistochemistry. HRD status was defined by a high loss of heterozygosity (LOH-high) or mutations in homologous recombination repair (HRR) genes. Associations between HRD and established ICI biomarkers (tumor mutational burden, PD-L1, deficient mismatch repair/microsatellite instability-high, immune cell fractions, and transcriptomic signatures) were assessed. Survival outcomes on ICI therapy were assessed in cutaneous melanoma using insurance claims data. RESULTS: Overall, among the melanoma subtypes, mucosal and acral melanoma had a greater prevalence of LOH-high than cutaneous (30.9% v 13.1% v 8.3%, P < .001). Generally, LOH-high in skin cancer did not correlate with mutations in HRR genes. Additionally, there was no significant association in ICI response biomarkers and HRD among patients with skin cancers. Furthermore, HRD was not associated with a prognostic advantage following IO (hazard ratio, 0.981 [CI, 0.80 to 1.20]; P = .854). CONCLUSION: HRD defines a biologically distinct subset of skin cancers and is not predictive of ICI response or improved outcomes. The high prevalence of HRD in acral and mucosal melanoma highlights the need to investigate HRD-directed therapies strategies in this distinct cohort, such as poly (ADP-ribose) polymerase inhibitors or platinum-based therapies.

20 May 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
MBMichael Bian
Michael Bian
GNGeorge Nassief
George Nassief
VRVictoria Hope Ruesch
Victoria Hope Ruesch
VGViraj Gorthi
Viraj Gorthi
FCFumiko Chino
Fumiko Chino
LRLuke D. Rothermel
Luke D. Rothermel
PURPOSE: The 2021 Federal Hospital Price Transparency Final Rule requires hospitals to publicly disclose payer-negotiated prices for services. Despite rising cutaneous melanoma incidence and strong association with geographic ultraviolet light exposure, price transparency for melanoma-specific care is incompletely understood. We assessed regional price compliance and variation among National Cancer Institute–designated Comprehensive Cancer Centers (NCI-CCCs) to inform clinician-patient cost discussions. METHODS: A cross-sectional analysis was conducted of private payer-specific negotiated prices in 2025 for 53 melanoma-related procedures using publicly available hospital price transparency files. Fifty-eight NCI-CCCs providing adult clinical care were included (data extracted January 1-March 31, 2025). Primary outcomes were markups relative to Medicare reimbursement and price dispersion across and within centers by billing code. Secondary outcomes included compliance with price transparency, markups, and price dispersion by US Census division. RESULTS: Overall, 47/58 centers (81.0%) were federally compliant, with lymph node procedures showing the highest median (IQR) markups relative to Medicare 7.9 (5.5-9.5). Diagnostic testing/imaging demonstrated the greatest price dispersion, with median (IQR) across-center and within-center ratios of 13.4 (9.5-16.6) and 11.2 (9.6-12.7), respectively. The Pacific division had the highest median price markups at 8.9 (3.7-13.4) and included five noncompliant centers. Across divisions, within- and across-center price dispersion were strongly correlated (ρ = 0.88; 95% CI, 0.53 to 1.00). CONCLUSION: The use of lymph node procedures, diagnostic testing, and imaging presents a key opportunity to mitigate financial toxicity for at-risk patients. Improved clinical accessibility of pricing data and policy intervention is still needed to advance patient-centered, value-driven care.

4 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAngela Anaeme
Angela Anaeme
KMKaren Moussa
Karen Moussa
AMAbdallah N. Mansour
Abdallah N. Mansour
GNGeorge Nassief
George Nassief
George AnsstasGeorge Ansstas
George Ansstas
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombination deficiency (HRD), which damages cells through absent or erroneous repair of double-stranded DNA breaks, is a prime example of such cellular dysfunction. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit these aberrancies in the cellular repair process by arresting the ability of the PARP enzyme to repair cellular and genetic damage, inducing the accumulation of DNA damage and cancer cell death. While the utility of PARP inhibitors has been established in many HRD-associated tumors — particularly breast, pancreatic, ovarian, and prostate cancer — less robust evidence exists for the efficacy of PARP inhibitors in melanoma. Increasing efforts are underway to investigate PARP inhibitors as a viable treatment option for advanced and metastatic melanoma, both as monotherapy and in combination with other agents such as immune checkpoint inhibitors and BRAF/MEK inhibitors. Though several gaps in our knowledge of the use of PARP inhibitors in melanoma still exist, promising headway is being made in our understanding of its efficacy and safety. Here, we present a review of the utility of PARP inhibitors in melanoma, current clinical trials, and future avenues for further exploration.